Allurion Technologies, Inc. (ALUR)
1.50
0.00 (0.00%)
USD |
NYSE |
Dec 18, 16:00
1.50
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 18.38M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -80.65% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.5091 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.4027 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA. |
| URL | http://www.allurion.com |
| Investor Relations URL | https://investors.allurion.com/overview/default.aspx |
| HQ State/Province | Massachusetts |
| Sector | Consumer Discretionary |
| Industry | Diversified Consumer Services |
| Next Earnings Release | Mar. 25, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA. |
| URL | http://www.allurion.com |
| Investor Relations URL | https://investors.allurion.com/overview/default.aspx |
| HQ State/Province | Massachusetts |
| Sector | Consumer Discretionary |
| Industry | Diversified Consumer Services |
| Next Earnings Release | Mar. 25, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |